BellesoeurA, CartonE, AlexandreJ, GoldwasserF, HuillardO: Axitinib in the treatment of renal cell carcinoma: design, development, and place in therapy. Drug Des Devel Ther, 2017; 11:2801–2811.
FengS, HuangY, ChenZ: Does VEGF secreted by leukemic cells increase the permeability of blood-brain barrier by disrupting tight-junction proteins in central nervous system leukemia?. Med Hypotheses, 2011; 76:618–621.
4.
ArgawAT, GurfeinBT, ZhangY: VEGF-mediated disruption of endothelial CLN-5 promotes blood-brain barrier breakdown. Proc Natl Acad Sci U S A, 2009; 106:1977–1982.
5.
NieB, NieT, HuiX, et al.: Visualization and quantification of browning using a Ucp1–2A-luciferase knock-in mouse model. Diabetes, 2017; 66:407–417.
6.
TingDT, LipsonD, PaulS, et al.: Aberrant overexpression of satellite repeats in pancreatic and other epithelial cancers. Science, 2011; 331:593–596.
7.
BersaniF, LeeE, KharchenkoPV, et al.: Pericentromeric satellite repeat expansions through RNA-derived DNA intermediates in cancer. Proc Natl Acad Sci U S A, 2015; 112:15148–15153.
8.
TyagiR, LiW, ParadesD, BianchetMA, NathA: Inhibition of human endogenous retrovirus-K by antiretroviral drugs. Retrovirology, 2017; 14:21.
9.
ReusK, MayerJ, SauterM, SchererD, Müller-LantzschN, MeeseE: Genomic organization of the human endogenous retrovirus HERV-K (HML-2.HOM) (ERVK6) on chromosome 7. Genomics, 2001; 72:314–320.
10.
ParmentierT, SienaertP: The use of triiodothyronine (T3) in the treatment of bipolar depression: a review of the literature. J Affect Disord, 2018; 229:410–414.
11.
PingitoreA, MastorciF, PiaggiP, et al.: Usefulness of triiodothyronine replacement therapy in patients with ST elevation myocardial infarction and borderline/reduced triiodothyronine levels (from the THIRST Study). Am J Cardiol, 2019; 123:905–912.
12.
TeixeiraRB, ZimmerA, de CastroAL, et al.: Long-term T3 and T4 treatment as an alternative to aerobic exercise training in improving cardiac function post-myocardial infarction. Biomed Pharmacother, 2017; 95:965–973.
13.
SircutaC, LazarA, AzamfireiL, BaranyiM, ViziES, BorbélyZ: Correlation between the increased release of catecholamines evoked by local anesthetics and their analgesic and adverse effects: role of K(+) channel inhibition. Brain Res Bull, 2016; 124:21–26.
14.
ZhouY, PanP, TanZY, JiYH: Voltage-gated sodium channels in sensory information processing. CNS Neurol Disord Drug Targets, 2019; 18:273–278.
15.
MaloneyMA, KunSS, KeensTG, PerezIA: Congenital central hypoventilation syndrome: diagnosis and management. Expert Rev Respir Med, 2018; 12:283–292.
16.
MoreiraTS, TakakuraAC, CzeislerC, OteroJJ: Respiratory and autonomic dysfunction in congenital central hypoventilation syndrome. J Neurophysiol, 2016; 116:742–752.
17.
ZhaoH, CottonJF, LongX, FengH-J: The effect of atomoxetine, a selective norepinephrine reuptake inhibitor, on respiratory arrest and cardiorespiratory function in the DBA/1 mouse model of SUDEP. Epilepsy Res, 2017; 137:139–144.
18.
ŁęgoszP, OtworowskiM, SibilskaA, et al.: Heterotopic ossification: a challenging complication of total hip arthroplasty: risk factors, diagnosis, prophylaxis, and treatment. Biomed Res Int, 2019; 2019:3860142.
19.
LiuL, AronsonJ, HuangS, et al.: Rosiglitazone inhibits bone regeneration and causes significant accumulation of fat at sites of new bone formation. Calcif Tissue Int, 2012; 91:139–148.
20.
ChoES, KimMK, SonYO, LeeKS, ParkSM, LeeJC: The effects of rosiglitazone on osteoblastic differentiation, osteoclast formation and bone resorption. Mol Cells, 2012; 33:173–181.
21.
BlauN: Genetics of phenylketonuria: then and now. Hum Mutat, 2016; 37:508–515.
22.
QuJ, YangT, WangE, et al.: Efficacy and safety of sapropterin dihydrochloride in patients with phenylketonuria: a meta-analysis of randomized controlled trials. Br J Clin Pharmacol, 2019; 85:893–899.
23.
MoghadamNH, SalehzadehS, TanzadehpanahH, SaidijamM, KarimiJ, KhazalpourS: In vitro cytotoxicity and DNA/HSA interaction study of triamterene using molecular modelling and multi-spectroscopic methods. J Biomol Struct Dyn, 2019; 37:2242–2253.
24.
ReddyMA, ZhangE, NatarajanR: Epigenetic mechanisms in diabetic complications and metabolic memory. Diabetologia, 2015; 58:443–455.
25.
ChengC, KobayashiM, MartinezJA, et al.: Evidence for epigenetic regulation of gene expression and function in chronic experimental diabetic neuropathy. J Neuropathol Exp Neurol, 2015; 74:804–817.
26.
PulyaS, AminSA, AdhikariN, BiswasS, JhaT, GhoshB: HDAC6 as privileged target in drug discovery: a perspective. Pharmacol Res, 2021; 163:105274.
27.
CastinettiF, GuignatL, GiraudP, et al.: Ketoconazole in Cushing's disease: is it worth a try?. J Clin Endocrinol Metab, 2014; 99:1623–1630.
28.
YoungJ, BertheratJ, VantyghemMC, et al.: Hepatic safety of ketoconazole in Cushing's syndrome: results of a Compassionate Use Programme in France. Compassionalte use Programme. Eur J Endocrinol, 2018; 178:447–458.
29.
FleseriuM, PivonelloR, ElenkovaA, et al.: Efficacy and safety of levoketoconazole in the treatment of endogenous Cushing's syndrome (SONICS): a phase 3, multicentre, open-label, single-arm trial. Lancet Diabetes Endocrinol, 2019; 7:855–865.
30.
TardifJC, RhéaumeE, Lemieux PerreaultLP, et al.: Pharmacogenomic determinants of the cardiovascular effects of dalcetrapib. Circ Cardiovasc Genet, 2015; 8:372–382.
31.
SchwartzGG, LeiterLA, BallantyneCM, et al.: Dalcetrapib reduces risk of new-onset diabetes in patients with coronary heart disease. J Diabetes Care, 2020; 43:1077–1084.
32.
MillardM, PathaniaD, ShabaikY, TaheriL, DengJ, NeamatiN: Preclinical evaluation of novel triphenylphosphonium salts with broad-spectrum activity. PLoS One, 2010; 5:e13131.
